PDGFB and neoplasm: In our pursuit of new prognostic biomarkers and potential targets for novel therapeutic strategies, we systematically assessed both PC tumor and stromal expression of PDGFR-β and its ligands PDGF-B and PDGF-D, as well as associations with clinical outcome in a large multicenter cohort of 535 prostatectomy patients.